Eosinophilic Biomarker Found for Aggressive IBD
|
By LabMedica International staff writers Posted on 14 Dec 2017 |
|
Image: Peripheral bloods smear showing five eosinophils, from a patient with eosinophilia (Photo courtesy of the Hospital for Sick Children, Toronto).
Peripheral blood eosinophilia (PBE) in inflammatory bowel disease is associated with ulcerative colitis (UC) and active disease. Little data exist on the long-term impact of PBE on disease course.
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Immunoassay Analyzer
Procise DX
Chromogenic Culture System
InTray™ COLOREX™ ECC
Latest Pathology News
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
Channels
Clinical Chemistry
view channel
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more
Molecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more
Immunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Microbiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read more
Pathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more
